Cytori Sells First U.S. StemSource(R) Cell Bank
A StemSource(R) Cell Bank sale includes a proprietary processing system and other related equipment, custom operating software, standard operating procedures and protocols (SOPs), installation and training. The StemSource(R) Cell Bank facilitates the preparation and storage of stem and regenerative cells from fat tissue using methods that have been optimized by Cytori, creating significant economic and process efficiencies.
Cautionary Statement Regarding Forward-Looking Statements
This communication includes forwardlooking statements regarding events, trends and business prospects, which may affect our future operating results and financial position. Such statements are subject to risks and uncertainties that could cause our actual results and financial position to differ materially. Some of these risks include clinical and regulatory uncertainties, including risks in the collection and results of clinical data, final clinical outcomes, dependence on third party performance, and other risks and uncertainties described under the "Risk Factors" in Cytori's Securities and Exchange Commission Filings on Form 10-K and 10-Q. We assume no responsibility to update or revise any forwardlooking statements to reflect events, trends or circumstances after the date they are made.
Cytori Therapeutics, Inc.
Cytori is a leader in providing patients and physicians around the world with medical technologies that harness the potential of adult regenerative cells from adipose tissue. The Celution(R) System family of medical devices and instruments is being sold into the European and Asian cosmetic and reconstructive surgery markets but is not yet available in the United States. Our StemSource(R) product line is sold globally for cell banking and research applications. www.cytori.com